Research & Literature

A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?

Postlewait LM, Baptiste GG, Ethun CG, et al.

Journal of surgical oncology 2016; (114(5)):576-580 doi:10.1002/jso.24369.

Pathophysiology and laboratory diagnosis of pernicious anemia.

Toh BH

Immunologic research 2017; (65(1)):326-330 doi:10.1007/s12026-016-8841-7.

Management of gastric and duodenal neuroendocrine tumors.

Sato Y, Hashimoto S, Mizuno K, et al.

World journal of gastroenterology 2016; (22(30)):6817-28 doi:10.3748/wjg.v22.i30.6817.

Neuroendocrine Tumors of the Stomach.

Corey B, Chen H

The Surgical clinics of North America 2017; (97(2)):333-343 doi:10.1016/j.suc.2016.11.008.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1793-1796 doi:10.2967/jnumed.117.192450.

Insights into gastric neuroendocrine tumors burden.

Thomaz Araújo TM, Barra WF, Khayat AS, de Assumpção PP

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2017; (29(2)):137-143 doi:10.21147/j.issn.1000-9604.2017.02.06.

Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.

Lawal IO, Ololade KO, Lengana T, et al.

Hellenic journal of nuclear medicine 2017; (20(2)):128-133 doi:10.1967/s002449910553.

Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.

Klöppel G, La Rosa S

Virchows Archiv : an international journal of pathology 2018; (472(3)):341-349 doi:10.1007/s00428-017-2258-0.

GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE.

Dias AR, Azevedo BC, Alban LBV, et al.

Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2017; (30(2)):150-154 doi:10.1590/0102-6720201700020016.

Gastrinomas: Medical or Surgical Treatment.

Norton JA, Foster DS, Ito T, Jensen RT

Endocrinology and metabolism clinics of North America 2018; (47(3)):577-601 doi:10.1016/j.ecl.2018.04.009.

The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.

Sorbye H, Baudin E, Perren A

Endocrinology and metabolism clinics of North America 2018; (47(3)):683-698 doi:10.1016/j.ecl.2018.05.001.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Rindi G, Klimstra DS, Abedi-Ardekani B, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(12)):1770-1786 doi:10.1038/s41379-018-0110-y.

The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective.

Massironi S, Zilli A, Elvevi A, Invernizzi P

Autoimmunity reviews 2019; (18(3)):215-222 doi:10.1016/j.autrev.2018.08.011.

Gastric carcinoids: Does type of surgery or tumor affect survival?

Crown A, Kennecke H, Kozarek R, et al.

American journal of surgery 2019; (217(5)):937-942 doi:10.1016/j.amjsurg.2018.12.057.

[A 3mm Gastric Neuroendocrine Tumor That Metastasized to a Lymph Node].

Fukui Y, Kato Y, Okazaki Y, et al.

Gan to kagaku ryoho. Cancer & chemotherapy 2018; (45(13)):1839-1841.

Gastric Neuroendocrine Tumors (Carcinoids).

Gluckman CR, Metz DC

Current gastroenterology reports 2019; (21(4)):13 doi:10.1007/s11894-019-0684-7.

Diagnostic fficiency of 68Ga-DOTATATE PET/CT as ompared to 99mTc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors.

Fallahi B, Manafi-Farid R, Eftekhari M, et al.

Asia Oceania journal of nuclear medicine & biology 2019; (7(2)):129-140 doi:10.22038/AOJNMB.2019.39392.1263.

Multifocal G1-G2 gastric neuroendocrine tumors: Differentiating between Type I, II and III, a clinicopathologic review.

Algashaamy K, Garcia-Buitrago M

World journal of clinical cases 2019; (7(17)):2413-2419 doi:10.12998/wjcc.v7.i17.2413.

Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.

Yan S, Liu T, Li Y, et al.

Annals of translational medicine 2019; (7(20)):545 doi:10.21037/atm.2019.09.114.

Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.

Daniels LM, Khalili M, Morano WF, et al.

World journal of surgical oncology 2019; (17(1)):213 doi:10.1186/s12957-019-1758-6.

Gastrinoma in multiple endocrine neoplasia type 1 after total pancreatectomy: A case report.

Gong S, Li Z, Liu XB, et al.

Medicine 2019; (98(50)):e18275 doi:10.1097/MD.0000000000018275.

Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.

Rossi RE, Invernizzi P, Mazzaferro V, Massironi S

United European gastroenterology journal 2020; (8(2)):140-147 doi:10.1177/2050640619890465.

Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.

Trinh VQ, Shi C, Ma C

Histopathology 2020; (77(6)):865-876 doi:10.1111/his.14220.

Endoscopic Features of Early-stage Autoimmune Gastritis.

Kato M

Internal medicine (Tokyo, Japan) 2020; (59(23)):2969-2970 doi:10.2169/internalmedicine.5603-20.

Gastric neuroendocrine tumor: A practical literature review.

Roberto GA, Rodrigues CMB, Peixoto RD, Younes RN

World journal of gastrointestinal oncology 2020; (12(8)):850-856 doi:10.4251/wjgo.v12.i8.850.

New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia.

La Rosa S, Solcia E

Histopathology 2020; (77(6)):862-864 doi:10.1111/his.14226.

Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours.

Li YL, Qiu XD, Chen J, et al.

World journal of gastrointestinal oncology 2020; (12(12)):1416-1427 doi:10.4251/wjgo.v12.i12.1416.

Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor.

Noh JH, Kim DH, Yoon H, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(10)):2495-2502 doi:10.1007/s11605-021-04997-0.

Comparison of Survival and Patterns of Recurrence in Gastric Neuroendocrine Carcinoma, Mixed Adenoneuroendocrine Carcinoma, and Adenocarcinoma.

Lin J, Zhao Y, Zhou Y, et al.

JAMA network open 2021; (4(7)):e2114180 doi:10.1001/jamanetworkopen.2021.14180.

AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review.

Shah SC, Piazuelo MB, Kuipers EJ, Li D

Gastroenterology 2021; (161(4)):1325-1332.e7 doi:10.1053/j.gastro.2021.06.078.

Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

Rossi RE, Elvevi A, Citterio D, et al.

World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

Gastric Neuroendocrine Tumor Mimicking Gastrointestinal Stromal Tumor: A Case Report.

Lee J, Oh SJ

Case reports in oncology 2021; (14(3)):1271-1276 doi:10.1159/000518078.

A Modified T-Stage Classification for Gastric Neuroendocrine Tumors.

Yang T, Fong ZV, Pak L, et al.

The Journal of surgical research 2022; (270()):486-494 doi:10.1016/j.jss.2021.10.002.

Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Deprez PH, Moons LMG, OʼToole D, et al.

Endoscopy 2022; (54(4)):412-429 doi:10.1055/a-1751-5742.

Type-1 Grade 2 Multi-Focal Gastric Neuroendocrine Tumors Secondary to Chronic Autoimmune Gastritis.

Yu Z, Wang A, Hu C, et al.

Frontiers in medicine 2022; (9()):856125 doi:10.3389/fmed.2022.856125.

Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.

Exarchou K, Hu H, Stephens NA, et al.

Endocrine 2022; (78(1)):186-196 doi:10.1007/s12020-022-03143-3.

Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

Kandathil A, Subramaniam RM

PET clinics 2023; (18(2)):189-200 doi:10.1016/j.cpet.2022.11.001.

Optimal postoperative surveillance strategies for cancer survivors with gastric neuroendocrine carcinoma based on individual risk: a multicenter real-world cohort study.

Xu BB, He XY, Zhou YB, et al.

International journal of surgery (London, England) 2023; (109(6)):1668-1676 doi:10.1097/JS9.0000000000000401.

Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs.

Laffi A, Lania AGA, Ragni A, et al.

Cancers 2023; (15(8)) doi:10.3390/cancers15082202.

Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?

Cavalcoli F, Gallo C, Coltro LA, et al.

Medicina (Kaunas, Lithuania) 2023; (59(10)) doi:10.3390/medicina59101757.

Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.

Guo X, Zhao X, Huang G, Yu Y

Digestive diseases and sciences 2024; (69(1)):27-35 doi:10.1007/s10620-023-08180-0.

Management of Gastric Neuroendocrine Tumors: A Review.

Sok C, Ajay PS, Tsagkalidis V, et al.

Annals of surgical oncology 2024; (31(3)):1509-1518 doi:10.1245/s10434-023-14712-9.

Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.

Chen YY, Guo WJ, Shi YF, et al.

BMC gastroenterology 2023; (23(1)):440 doi:10.1186/s12876-023-03079-6.

Familial multiple endocrine neoplasia type 1 with intrathoracic low-grade fibromyxoid sarcoma.

Ishida H, Funaki S, Taniguchi S, et al.

Surgical case reports 2024; (10(1)):16 doi:10.1186/s40792-024-01809-w.

Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.

Huang J, Liu H, Yang D, et al.

Chinese medical journal 2024; (137(6)):720-728 doi:10.1097/CM9.0000000000003029.

[Current WHO classification (2022) of neuroendocrine neoplasms].

Buchstab O, Knösel T

Radiologie (Heidelberg, Germany) 2024; (64(7)):531-535 doi:10.1007/s00117-024-01295-z.

Head-to-head: Should Ki67 proliferation index be included in the formal classification of pulmonary neuroendocrine neoplasms?

Pelosi G, Travis WD

Histopathology 2024; (85(4)):535-548 doi:10.1111/his.15206.

Predictors of Outcomes in Gastric Neuroendocrine Tumors: A Retrospective Cohort.

Ortigão R, Afonso LP, Pimentel-Nunes P, et al.

GE Portuguese journal of gastroenterology 2024; (31(4)):236-245 doi:10.1159/000530684.

Gastric neuroendocrine tumors: 20-Year experience in a reference center.

Ravizza D, Giunta M, Sala I, et al.

Journal of neuroendocrinology 2024; (36(12)):e13440 doi:10.1111/jne.13440.

Gastric Neuroendocrine Tumors and Pernicious Anemia: A Case Report and Literature Review.

Rudolph JJ, Agyei O, Telvizian T, Ghaneie A

Cureus 2024; (16(11)):e73553 doi:10.7759/cureus.73553.

Progress report on multiple endocrine neoplasia type 1.

Halperin R, Tirosh A

Familial cancer 2025; (24(1)):15 doi:10.1007/s10689-025-00440-4.

Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.

Christodoulidis G, Kouliou MN, Ragias D, et al.

World journal of clinical oncology 2025; (16(5)):104577 doi:10.5306/wjco.v16.i5.104577.

Gastric neuroendocrine tumors arising from chronic proton pump inhibitor use: characteristics and outcomes of a fourth subtype.

Egbert LK, Kartik A, Wasif N, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2025; (29(11)):102207 doi:10.1016/j.gassur.2025.102207.

The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm.

Dell'Unto E, Mandair D, Riding G, et al.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2026; (58(1)):119-124 doi:10.1016/j.dld.2025.09.011.

The Association Between Proton Pump Inhibitor Use and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review.

Moeinipour Y, Abedi F, Sadeghi M, et al.

Journal of gastrointestinal cancer 2025; (56(1)):214 doi:10.1007/s12029-025-01328-3.

Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.

Broechner A, Maier AD, Mirian C, et al.

Journal of neuropathology and experimental neurology 2026; (85(3)):253-266 doi:10.1093/jnen/nlaf131.

Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist's roadmap for the clinician.

Wang CL, Zeng M, Luo Y

World journal of gastroenterology 2025; (31(48)):115244 doi:10.3748/wjg.v31.i48.115244.

Vitamin D Deficiency and Replacement Challenges in Type 1 Gastric Neuroendocrine Tumors: A Comparative Study.

Benevento E, Coletta M, Liccardi A, et al.

Nutrients 2026; (18(2)) doi:10.3390/nu18020281.

A case of gastric neuroendocrine tumor with an unusual morphology.

Ohashi T, Okimoto K, Matsusaka K, et al.

Clinical journal of gastroenterology 2026; (19(2)):446-450 doi:10.1007/s12328-026-02289-1.

Clinical Outcomes of Endoscopic Resection for Gastric and Duodenal Neuroendocrine Tumors.

Chang JW, Jung DH, Yoon JH, et al.

Gut and liver 2026; doi:10.5009/gnl250378.